Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis.
Julie Ho, George N Okoli, Rasheda Rabbani...
https://pubmed.ncbi.nlm.nih.gov/34860468/Actively Recruiting
Led by University of Sydney · Updated on 2026-08-31
540
Participants Needed
30
Research Sites
N/A
Total Duration
Researchers are studying the best steroid dose to treat acute T cell mediated rejection TCMR in people who have had kidney or kidney-pancreas transplants. TCMR is a type of rejection where the bodys immune system attacks the transplanted organ, which can cause serious complications or organ failure. This international, multi-center trial aims to find the lowest effective and safe steroid dose to manage this condition, addressing a long-standing question in transplant care. The trial compares four treatment approaches that differ in doses of intravenous methylprednisolone IV MP and oral prednisone taper. Participants receive either a high or low dose of IV MP for three days followed by a high or low dose of oral prednisone for seven days, then return to standard prednisone. This factorial design allows evaluation of both drugs dose effects. The study is sponsored by the University of Sydney and involves collaboration among several international transplant societies. Participants will be closely monitored with biopsies and blood tests to assess rejection resolution and kidney function over 12 weeks. Researchers will also track survival, kidney filtration rates, urine protein levels, infection rates, quality of life, and other health outcomes up to 48 weeks. The study includes regular visits and evaluations to ensure safety and collect data on treatment effects and side effects during the trial period.
CONDITIONS
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
N
NHMRC Clinical Trials Centre THE UNIVERSITY OF SYDNEY
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Sydney
Lead Sponsor
University of Manitoba
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Approximately 12 weeks
Participants receive assigned doses of intravenous methylprednisolone for 3 days followed by oral prednisone for 7 days, then return to standard prednisone dosing.
Regular visits for monitoring and assessments
Duration - Up to 48 weeks
Participants are monitored for kidney function, rejection resolution, infections, and quality of life up to 48 weeks after treatment starts.
Periodic visits for health assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Julie Ho, George N Okoli, Rasheda Rabbani...
https://pubmed.ncbi.nlm.nih.gov/34860468/Chris Wiebe, Vasilis Kosmoliaptsis, Denise Pochinco...
https://pubmed.ncbi.nlm.nih.gov/30414349/Chris Wiebe, David N Rush, Ian W Gibson...
https://pubmed.ncbi.nlm.nih.gov/32185878/Angela Ju, Michelle A Josephson, Zeeshan Butt...
https://pubmed.ncbi.nlm.nih.gov/30300284/Peter W Nickerson, Robert Balshaw, Chris Wiebe...
https://pubmed.ncbi.nlm.nih.gov/32956576/Allison Tong, Benedicte Sautenet, Emilio D Poggio...
https://pubmed.ncbi.nlm.nih.gov/29470347/C Wiebe, I W Gibson, T D Blydt-Hansen...
https://pubmed.ncbi.nlm.nih.gov/22429309/Brian J Nankivell, Meena Shingde, Karen L Keung...
https://pubmed.ncbi.nlm.nih.gov/29194971/Allison Tong, John Gill, Klemens Budde...
https://pubmed.ncbi.nlm.nih.gov/28737661/Angela Ju, Bi Yang Chow, Angelique F Ralph...
https://pubmed.ncbi.nlm.nih.gov/30664327/University of Sydney
Lead Sponsor
University of Manitoba
Collaborating Sponsor